Non-interventional Study of the Effectiveness and Safety of Jardiance in Patients With Heart Failure (HF) of Reduced Ejection Fraction (HFrEF) Compared to Guideline-recommended Non-SGLT2i Therapy Regimens in China: A Sub-study of the Postmarketing Study of Jardiance Among Patients With Heart Failure in China

This study is to provide the effectiveness and safety evidence in patients with heart failure of reduced ejection fraction (HFrEF) initiating Jardiance in real clinical practice in a larger Chinese population.
The primary objective is to compare the risk of the composite outcome of cardiovascular (CV) death or hospitalisation for heart failure (HHF) in heart failure with reduced ejection fraction (HFrEF) patients initiating Jardiance with propensity score (PS) matched HFrEF patients initiating guideline-recommended non-sodium-glucose cotransporter-2 inhibitors (SGLT2i) medications (angiotensin-converting-enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB)/angiotensin receptor-neprilysin inhibitor (ARNI), betablockers, and mineralocorticoid receptor antagonist (MRA)) in China, measured by the hazard ratio of the two groups.

Start Date31 Jan 2028

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT03867487

/ Not yet recruitingPhase 2IIT

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

Start Date01 May 2027

Sponsor / Collaborator

Ann & Robert H. Lurie Children's Hospital of Chicago

NCT07857772

/ Not yet recruitingPhase 2IIT

A Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction

The SPECTRA-HFpEF Study is a randomized, double-blind, Phase 2 clinical study designed to evaluate and compare the biological effects of vicadrostat in combination with empagliflozin, empagliflozin alone, and spironolactone in combination with empagliflozin in adults with heart failure and preserved ejection fraction. The study will enroll approximately 200 participants with chronic heart failure, New York Heart Association Class II to IV symptoms, and left ventricular ejection fraction greater than 40%. The primary objective is to determine whether treatment with vicadrostat/empagliflozin produces differential changes in circulating plasma proteins compared with spironolactone/empagliflozin, using a broad proteomic panel measured over the course of treatment. These proteomic changes may help identify biological pathways affected by each treatment strategy, including pathways related to inflammation, myocardial fibrosis and remodeling, kidney function, cardiac stress, and aldosterone-related signaling.
Participants will complete an approximately 26-week study period, including screening, treatment, and follow-up phases. After screening and any required washout of prior sodium-glucose cotransporter 2 inhibitor therapy, participants will receive open-label empagliflozin and will be randomized in a blinded manner to receive vicadrostat or placebo during the first treatment period. During the second treatment period, participants will receive either continued vicadrostat with empagliflozin or spironolactone with empagliflozin. During the third treatment period, vicadrostat or spironolactone will be discontinued while empagliflozin is continued. Blood and urine samples will be collected at specified visits to evaluate changes in proteomic markers, renin-angiotensin-aldosterone system biomarkers, collagen turnover markers, sex hormone markers, kidney function, proteinuria, inflammatory biomarkers, and cardiac stress biomarkers. Echocardiography and patient-reported health status assessments will also be performed to explore potential effects on cardiac structure, function, symptoms, and quality of life.
The study is intended to improve understanding of how aldosterone synthase inhibition with vicadrostat differs from mineralocorticoid receptor antagonism with spironolactone when each is used with empagliflozin in patients with heart failure and preserved ejection fraction. By comparing treatment-related proteomic and biomarker changes across study arms, the study may provide insight into mechanistic differences between these therapeutic approaches and help inform future development of targeted combination therapies for heart failure. Safety and tolerability will be monitored throughout the study through collection of adverse events, serious adverse events, vital signs, electrocardiograms, physical examinations, and clinical laboratory assessments, including kidney function and serum potassium monitoring.

Start Date01 Mar 2027

Sponsor / Collaborator

The Baim Institute for Clinical Research

100 Clinical Results associated with Empagliflozin

100 Translational Medicine associated with Empagliflozin

100 Patents (Medical) associated with Empagliflozin

4,317

Literatures (Medical) associated with Empagliflozin

01 Dec 2026·Journal of Cardiovascular Translational Research

Low-dose Empagliflozin Does Not Modify Myocardial Energetics and Function in a Large-animal Model of Hibernating Myocardium

Article

Author: Cepas, Pedro Luis ; Ibáñez, Borja ; Pérez-Camargo, Daniel ; Galán-Arriola, Carlos ; Cádiz, Laura ; García-Alvarez, Ana ; Sánchez-González, Javier ; Medina-Hernández, Danielle ; Pereda, Daniel

01 Dec 2026·NEUROTOXICOLOGY

Empagliflozin attenuates PTZ-induced neurotoxicity and enhances the protective effects of levetiracetam: Associations with NRF2/GPX4 and AMPK/ULK1/ LC3-II signaling

Article

Author: Elshal, Mahmoud ; Madkour, Ahmed H ; Abdelaziz, Rania R ; Nader, Manar A

PURPOSE:

To investigate the antiseizure and neuroprotective effects of empagliflozin (EMPA), administered alone or in combination with levetiracetam (LEV), in pentylenetetrazole (PTZ)-induced epilepsy model in rats.

METHODS:

A modified window-PTZ kindling model was used to investigate associated biochemical and molecular changes. Rats were assigned to six groups: control, PTZ, LEV (200 mg/kg), EMPA (3 mg/kg), EMPA (10 mg/kg) and EMPA (10 mg/kg) plus LEV (100 mg/kg) groups. Seizure severity, open-field behavior, hippocampal histopathology, oxidative stress markers, sodium-glucose cotransporter-2 (SGLT2) and gamma-aminobutyric acid (GABA) levels, nuclear factor erythroid 2-related factor 2 (NRF2) and glutathione peroxidase 4 (GPX4) levels, unc-51-like kinase 1 (ULK1) and microtubule-associated protein 1 light chain 3-II (LC3-II) levels, and adenosine monophosphate-activated protein kinase (AMPK) activation were evaluated.

RESULTS:

EMPA reduced PTZ-induced seizure severity in a dose-related manner, with the higher dose producing greater suppression of seizure severity, improved locomotor and exploratory behavior, and attenuated hippocampal histopathological alterations. It also attenuated oxidative damage, improved antioxidant capacity, increased GABA levels, and reduced hippocampal SGLT2 expression. In addition, EMPA modulated NRF2 and GPX4 levels and was associated with changes in autophagy-related signaling, including increased AMPK activation and higher ULK1 and LC3-II levels. Although EMPA and LEV each provided partial protection, the combined regimen produced the most pronounced improvement across the evaluated outcomes.

CONCLUSION:

EMPA was associated with antiseizure and neuroprotective effects in PTZ-induced kindling epilepsy, particularly when combined with reduced-dose LEV (100 mg/kg). These findings suggest that EMPA may represent a promising candidate for further investigation as an adjunctive therapeutic approach in epilepsy.

01 Dec 2026·Journal of Cardiovascular Translational Research

Empagliflozin Improves Endothelial Function in an Ovariectomized Rat Model of Estrogen Deficiency

Article

Author: Aminuddin, Amilia ; Mokhtar, Mohd Helmy ; Ahmad, Mohd Faizal ; Hamid, Adila A ; Kumar, Jaya ; Ugusman, Azizah ; Mad Azli, Amanina Athirah

Cardiovascular disease risk increases after menopause, largely driven by estrogen deficiency-induced endothelial dysfunction. While sodium-glucose cotransporter 2 (SGLT2) inhibitors confer cardiovascular protection, their vascular effects under estrogen-deficient conditions remain unclear. This study investigated the effects of the SGLT2 inhibitor empagliflozin on vascular function in an ovariectomized (OVX) rat model of estrogen deficiency. Female Sprague-Dawley rats were assigned to control, OVX, OVX + vehicle, OVX + empagliflozin (10 mg/kg/day), and OVX + estradiol (20 µg/kg/day) groups for 28 days. Vascular reactivity was assessed using wire myography, alongside evaluation of endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) levels. OVX rats exhibited impaired endothelium-dependent vasorelaxation, increased vasoconstriction, reduced eNOS activation, and decreased NO bioavailability. Empagliflozin significantly improved vascular reactivity, enhanced eNOS activation, and restored NO levels, with effects comparable to estradiol. These findings identify empagliflozin as a potential non-hormonal therapeutic strategy for endothelial dysfunction in postmenopausal conditions.

360

News (Medical) associated with Empagliflozin

26 Oct 2026

·healthcare-digital.com

Boehringer & Microsoft: Developing AI Digital Patient Twins

Digital patient twins, a core focus of Microsoft and Boehringer Ingelheim's partnership, are a computational technology that could streamline clinical trial design and accelerate the generation of clinical evidence. Photograph credit: Sven Wolf Copyright notice: Boehringer Ingelheim Boehringer’s Shashank Deshpande says partnerships such as its Microsoft collaboration are crucial to realising “AI’s full potential in healthcare” German pharmaceutical giant Boehringer Ingelheim has set its sights on becoming a frontier AI company across human pharmaceuticals and animal health, placing AI and advanced computational techniques at the heart of its future strategy. Building partnerships with leading AI companies is central to achieving this ambition, bringing together pharmaceutical expertise and advanced technology to explore novel approaches to healthcare and drug development . Microsoft is among its latest collaborators. Announced during the Microsoft Frontier Tour in Cologne, Germany, the partnership will explore how digital patient twins could transform clinical development, potentially improving trial design and accelerating the generation of evidence for new medicines. Shashank Desphande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. Credit: Boehringer Ingelheim Shashank Desphande, Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer, sees partnerships between innovative technology and pharmaceutical firms as essential to unlocking AI’s potential in healthcare. Shashank met Microsoft CEO Satya Nadella at the event in Germany, and in a LinkedIn post following the meeting, Shashank writes: “One thing is becoming increasingly clear: realising AI’s full potential in healthcare will require more than technology alone. The most impactful innovations rarely emerge in isolation. They happen when different expertise, perspectives and capabilities come together - around a shared ambition.” He continues: “We have an opportunity to explore new approaches to clinical development, advance the use of AI across everyday work and build the digital foundations that can accelerate innovation across research, operations and in the end patient care. “Our ambition is not simply to adopt new technology. It is to explore how AI can help accelerate the generation of knowledge, improve decision-making and ultimately translate scientific discoveries into patient impact.” “ One thing is becoming increasingly clear: realising AI’s full potential in healthcare will require more than technology alone. ” Shashank Deshpande Chairman of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim What are digital patient twins? Digital patient twins , a central focus of the partnership, are a computational technology that could streamline clinical trial design and accelerate the generation of clinical evidence. Digital patient twins are AI-enabled computational models of individual patients, using clinical and other relevant data to simulate disease progression and predict how health outcomes could change under different scenarios. By creating digital representations of patients, researchers can explore potential disease trajectories and treatment outcomes, supporting more informed decisions in clinical development. Boehringer Ingelheim: AI and Digital Patient Twins Founded in 1885: Boehringer Ingelheim is a biopharmaceutical company operating across human pharmaceuticals and animal health. AI ambition: The company aims to become a frontier AI company by embedding AI responsibly across its value chain. Digital patient twins: Its partnership with Microsoft will explore computational models that use patient data to predict disease progression and potential health outcomes. Research priorities: The collaboration will investigate disease-progression modelling, predictive outcome modelling and advanced clinical trial simulation, beginning with lung health. Potential benefits: The research could improve trial design, reduce the number of patients needed in control groups and accelerate clinical evidence generation, while maintaining patient safety and regulatory standards Boehringer and Microsoft will investigate how these models could strengthen clinical research, focusing on disease-progression modelling, predictive outcome modelling and advanced clinical trial simulations. The collaboration will also explore the potential for digital patient twins to support synthetic and hybrid control arms, which use existing patient data , either alone or combined with data from participants in a conventional control group, to provide a basis for comparison with an investigational treatment. The research aims to establish the scientific and technical feasibility of these approaches through modelling, prototyping and evidence generation across several disease and therapeutic areas, beginning with lung health. If successful, the work could reduce the number of patients needed in control groups, improve clinical trial design and accelerate the generation of evidence needed to evaluate new medicines. Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim. Credit: LinkedIn Dr Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, says the partnership will allow Boehringer to pursue a more patient-centric clinical research approach. “Boehringer Ingelheim is developing the richest pipeline in its history, and it is our goal to make clinical research more responsive to patients’ unmet needs. Exploring AI-enabled approaches, including the future potential of digital patient twins, could support more patient-centric, informed and efficient clinical research,” says Lykke. Deepening its Microsoft partnership The digital patient twin-focused partnership builds on Boehringer’s enterprise-wide deployment of Microsoft Copilot, which is one of the largest in the pharmaceutical industry, according to the company. In addition, Boehringer and Microsoft are partnering on security and data centre modernisation, alongside projects involving Boehringer’s Animal Health division, company-wide business processes and technology infrastructure. “Successful AI adoption depends on more than technology alone,” says Harsha Deshmukh, who is a Member of the Board of Managing Directors at Boehringer Ingelheim and responsible for IT and Global Business Services. “What matters is enabling our employees to use AI responsibly and unlock its potential through scalable solutions across the complete value chain and all business units.” Boehringer Ingelheim - key partners Eli Lilly CEO : David A. Ricks | HQ : Indianapolis, Indiana Eli Lilly and Boehringer Ingelheim have a long-standing pharmaceutical alliance focused on developing and commercialising medicines for type 2 diabetes and related conditions. Their collaboration combines expertise in drug discovery, clinical development and commercialisation, including the diabetes medicine Jardiance (empagliflozin), which is also used to treat heart failure and chronic kidney disease. The alliance demonstrates how pharmaceutical companies can pool expertise to develop treatments for complex, long-term conditions. Owkin CEO : Thomas Clozel | HQ : Paris, France Owkin is an AI biotechnology company developing tools to accelerate drug discovery and development. In September 2026, it signed a licensing agreement with Boehringer Ingelheim, giving the pharmaceutical company access to its K Pro AI Scientist platform and multimodal patient data. The collaboration will support research across oncology and immunology, building on an earlier pilot that explored tumour biology. Company portals Boehringer Ingelheim Microsoft Executives Lykke Hinsch Gylvin, MD EMBA Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim Satya Nadella Member Board Of Trustees Shashank Deshpande Chairman of the Board of Managing Directors & Head of Human Pharma

License out/in

21 Oct 2026

·www.biospace.com

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease

-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation -- -- Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition -- THE WOODLANDS, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today highlighted findings from two newly reported preclinical studies that provide additional insight into the biological effects of sotagliflozin, Lexicon's first-in-class dual SGLT1 and SGLT2 inhibitor. The investigator-initiated studies, funded by Lexicon and conducted by independent academic investigators, demonstrated favorable effects of sotagliflozin on key pathways involved in hypertrophic cardiomyopathy (HCM) and thrombotic cardiovascular events. The first study, published in the Journal of Molecular and Cellular Cardiology Plus 1 , found that sotagliflozin improved cardiac structure and function in a mouse model of hypertrophic cardiomyopathy, while reducing oxidative stress and upregulating mitochondrial gene sets associated with energy production in myocardial tissues. Investigators reported that sotagliflozin normalized measures of diastolic function, reversed progression of cardiac hypertrophy and reduced cardiac fibrosis, findings that support further evaluation of its potential in HCM. The second study, published in the Journal of Clinical Investigation 2 , demonstrated that sotagliflozin, but not the selective SGLT2 inhibitor empagliflozin, reduced platelet activation and thrombus formation in ex vivo human blood and animal models, including an SGLT1 gene murine knockout model, without adversely affecting normal hemostasis. These findings provide additional insight into the differentiated biology of dual SGLT1 and SGLT2 inhibition and may provide support for previously observed reductions in myocardial infarction and stroke risk associated with sotagliflozin in heart failure and Type 2 diabetes clinical studies “These studies add to a growing body of evidence demonstrating the broad biological effects of sotagliflozin across multiple pathways relevant to cardiovascular disease,” said Craig Granowitz, M.D., Ph.D., senior vice president and chief medical officer of Lexicon. “From cardiac remodeling and mitochondrial function to platelet activation and thrombosis, the findings continue to expand our understanding of the differentiated biology associated with dual SGLT1 and SGLT2 inhibition and further support the scientific rationale for evaluating sotagliflozin in areas of significant unmet need, including hypertrophic cardiomyopathy.” Lexicon is currently evaluating sotagliflozin in the ongoing Phase 3 SONATA-HCM trial in patients with symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy. Topline results are expected in the first quarter of 2027. About Sotagliflozin Discovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also currently under investigation for hypertrophic cardiomyopathy (HCM). About Lexicon Pharmaceuticals Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines. For additional information, please visit . Safe Harbor Statement This press release contains “forward-looking statements,” including statements relating to the research, development and therapeutic and commercial potential of sotagliflozin in hypertrophic cardiomyopathy. In addition, this press release may also contain forward-looking statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. For Media Inquiries: Dave Belian Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com 1 Qin F, et al. Sotagliflozin corrects myocardial phenotype, mitochondrial gene expression and oxidative stress in mice with hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology Plus. 2026;100873. doi:10.1016/j.jmccpl.2026.100873. 2 Stanger L, et al. SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis. Journal of Clinical Investigation. 2026. In-Press Preview. doi:10.1172/JCI201899.

Phase 3Clinical Result

24 Sep 2026

·www.prnewswire.com

Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight

A diversified late-stage pipeline encompassing endothelin receptor antagonists, aldosterone synthase inhibitors such as lorundrostat, APOL1 inhibitors including MZE829, and cell therapy approaches such as rilparencel is poised to intensify competition, with each modality addressing mechanisms that complement the established SGLT2 inhibitor/MRA backbone. The CKD market expansion is further expected to be supported by rising diagnosis rates, earlier screening based on UACR and eGFR, and broader adoption of combination therapies. LAS VEGAS, Sept. 24, 2026 /PRNewswire/ -- Treatment of chronic kidney disease (CKD) focuses on slowing disease progression toward kidney failure, reducing cardiovascular risk, and addressing complications such as anemia and mineral bone disorders. SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and emerging aldosterone synthase inhibitor combinations are increasingly replacing single-agent RAS blockade, driven by their improved renal and cardiovascular outcomes. Approved therapies in the CKD market include empagliflozin (JARDIANCE) (Boehringer Ingelheim and Eli Lilly), finerenone (KERENDIA) (Bayer), dapagliflozin (FARXIGA/FORXIGA) (AstraZeneca), among others. Find out more about what is the latest treatment for chronic kidney disease @ The pharmaceutical companies involved in the emerging pipeline include AstraZeneca (zibotentan/dapagliflozin), Boehringer Ingelheim (vicadrostat + empagliflozin), Mineralys Therapeutics (lorundrostat), ProKidney (rilparencel), Disc Medicine (DISC-0974), and others. Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that Rilparencel and MZE829 represent potential disease-modifying and precision-genetic opportunities, respectively, with the potential to achieve premium positioning in advanced and APOL1-driven CKD if pivotal data continue to be positive. Thakur further added that DISC-0974 could establish a new anemia-focused revenue segment within the broader CKD market, with limited direct competition from therapies primarily targeting SGLT2i- and MRA-focused mechanisms. Although SGLT2 inhibitors, non-steroidal MRAs, and RAS blockade have been approved, a significant proportion of CKD patients continue to progress to kidney failure, while the disease remains substantially underdiagnosed. This highlights the need for more effective therapies to slow or halt disease progression, alongside improved strategies for early detection and diagnosis. Reflecting the growing disease burden and significant unmet medical needs, the chronic kidney disease market across the seven major markets, comprising the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, was valued at approximately USD 5 billion in 2025. The market is projected to expand at a significant CAGR during the forecast period through 2036, driven by the increasing prevalence of CKD, rising awareness and diagnosis, advances in disease management, and the introduction of novel therapies targeting disease progression and associated complications. Below, we highlight 5 promising emerging therapies poised to reshape the future of the chronic kidney disease market. AstraZeneca's Zibotentan/Dapagliflozin Endothelin receptor antagonist/SGLT2 inhibitor Zibotentan/Dapagliflozin, developed by AstraZeneca, is an investigational oral combination therapy being studied in adults with CKD. The therapy combines zibotentan, an endothelin receptor antagonist, with dapagliflozin, an SGLT2 inhibitor, with the goal of improving kidney outcomes by targeting complementary mechanisms involved in CKD progression. Following encouraging Phase IIb ZENITH-CKD results, which demonstrated up to a 52.5% reduction in urine protein markers, enrollment in the Phase III ZENITH High Proteinuria trial was completed in late 2024, with topline results anticipated in 2027. Boehringer Ingelheim's Vicadrostat (BI 690517) + Empagliflozin Aldosterone synthase inhibitor/SGLT2 inhibitor Vicadrostat + empagliflozin, developed by Boehringer Ingelheim, is an investigational combination therapy being studied in adults with CKD. In a Phase II CKD trial conducted in 2023, the combination demonstrated promising results, with full data showing a significant reduction of up to 39.5% in excessive urinary protein levels (albuminuria) compared with placebo. The vicadrostat and empagliflozin combination may provide a new treatment option for people living with CKD. Discover more about the chronic kidney disease treatment market @ Chronic Kidney Disease Drugs Market ProKidney's Rilparencel Stabilizes eGFR decline ProKidney is developing rilparencel, an investigational cell therapy product designed to preserve kidney function by stabilizing estimated glomerular filtration rate (eGFR) in patients with advanced CKD. The company is developing rilparencel with the potential to delay or prevent the need for dialysis. Rilparencel is a percutaneous, minimally invasive injectable product prepared from the patient's own kidney cells. As rilparencel is prepared from the patient's own cells, immunosuppressive therapy to prevent rejection is not required. To date, clinical studies suggest that rilparencel treatment in patients with advanced CKD and diabetes may positively impact kidney function by stabilizing eGFR or attenuating the rate of eGFR decline. Mineralys Therapeutics' Lorundrostat Aldosterone synthase inhibitor Lorundrostat, developed by Mineralys Therapeutics, is an investigational oral aldosterone synthase inhibitor being studied in adults with CKD. The therapy selectively inhibits aldosterone production, targeting hormonal pathways implicated in the progression of CKD. In January 2026, Mineralys Therapeutics provided a corporate update outlining recent and anticipated clinical and regulatory milestones for Lorundrostat in CKD and related conditions. In November 2025, Mineralys Therapeutics reported data on Lorundrostat in CKD and hypertension at ASN Kidney Week 2025, organized by the American Society of Nephrology. In June 2025, Mineralys Therapeutics announced positive topline results from the Phase II EXPLORE-CKD trial evaluating Lorundrostat in patients with CKD and albuminuria. To know more about what new drug approvals have there been for chronic kidney disease treatment in the US recently, visit @ Chronic Kidney Disease Medications Disc Medicine's DISC-0974 DISC-0974 is an investigational anti-hemojuvelin (HJV) monoclonal antibody designed to suppress hepcidin production and enhance iron levels for the treatment of anemia of inflammation. DISC-0974 was in-licensed from AbbVie and is being evaluated in multiple clinical studies. Disc completed a Phase 1 clinical study in healthy volunteers and has advanced the program into development for multiple forms of anemia of inflammation. The company has initiated a Phase 1b/2 study in patients with anemia of myelofibrosis (MF) and a Phase 2 study in patients with anemia of inflammatory bowel disease (IBD). Download the report to understand the top chronic kidney disease drugs manufacturer @ Chronic Kidney Disease Drugs Supplier Source: Chronic Kidney Disease Market Report Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CKD companies, including Boehringer Ingelheim, Eli Lilly, Bayer, AstraZeneca, Mineralys Therapeutics, ProKidney, Maze Therapeutics, Regeneron Pharmaceuticals, Disc Medicine, and others. Related Reports Chronic Kidney Disease Clinical Trial Analysis Chronic Kidney Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CKD companies, including Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent, and others. Anemia in Chronic Kidney Disease Market Anemia in Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others. Moderate and Severe Chronic Kidney Disease Market Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, and others. End-Stage Renal Disease Market End-Stage Renal Disease Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key ESRD companies, including Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA , and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 SOURCE DelveInsight Business Research, LLP 21% more press release views with Request a Demo

Clinical ResultPhase 2Cell TherapyPhase 1

100 Deals associated with Empagliflozin

External Link

KEGG	Wiki	ATC	Drug Bank
D10459	Empagliflozin	A10BK03	DB09038

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	China	Boehringer Ingelheim GmbH	26 May 2023
Cardiovascular Diseases	China	Boehringer Ingelheim International GmbH	26 May 2023
Heart failure with normal ejection fraction	China	Boehringer Ingelheim International GmbH	30 Aug 2022
Heart failure with normal ejection fraction	China	Boehringer Ingelheim (China) Investment Co., Ltd.	30 Aug 2022
Heart failure with reduced ejection fraction	China	Boehringer Ingelheim GmbH	10 Jun 2022
Heart failure with reduced ejection fraction	China	Boehringer Ingelheim International GmbH	10 Jun 2022
Chronic heart failure	European Union	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Iceland	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Liechtenstein	Boehringer Ingelheim International GmbH	22 May 2014
Chronic heart failure	Norway	Boehringer Ingelheim International GmbH	22 May 2014
Chronic Kidney Diseases	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014
Diabetes Mellitus, Type 2	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014
Heart Failure	Australia	Boehringer Ingelheim Pty Ltd.	30 Apr 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Defects, Congenital	Phase 3	Canada	Boehringer Ingelheim GmbH	29 May 2026
Glycosuria, Renal	Phase 3	Egypt	Tanta University	25 May 2023
Schizophrenia	Phase 3	Egypt	Tanta University	25 May 2023
Metabolic Dysfunction Associated Steatohepatitis	Phase 3	Egypt	Tanta University	01 Nov 2022
Hypoglycemia	Phase 3	Switzerland	Boehringer Ingelheim GmbH	11 Mar 2022
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim GmbH	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim Pharma GmbH & Co., KG	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Boehringer Ingelheim International GmbH	16 Dec 2020
Acute myocardial infarction	Phase 3	United States	Eli Lilly & Co.	16 Dec 2020
Acute myocardial infarction	Phase 3	China	Eli Lilly & Co.	16 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02383238 \| NCT02471963 (Pubmed \| Endocrinol Diabetes Metab)	Phase 3	Diabetes Mellitus, Type 2	123	Empagliflozin	fcrbczvvis(udrwkxjlqp) = yjifuwbsgi njafmdaioo (ozwzfeediy ) View more	Positive	01 Nov 2026
				Dapagliflozin	jivfzpepbl(ovaaglgpsh) = zjxpteojbw xhbfhrfgwe (bzppiyvtuw ) View more
NCT05614115 (CTgov)	Phase 1	Functional disorder \| Diabetes Mellitus \| Kidney Failure, Chronic	62	Empagliflozin (Empagliflozin 10mg)	xtmnkkawph = qwfuumyeei zdpktdmbri (gywefpwhgk, amkakwojdl - bhxyfzskot) View more	-	30 Oct 2026
				Empagliflozin (Empagliflozin 25mg)	xtmnkkawph = qzvkszwelw zdpktdmbri (gywefpwhgk, azmrfysmhq - zbnmcpfaxl) View more
ASN2026	Phase 2	Polycystic Kidney, Autosomal Dominant	50	Empagliflozin 25mg	uyewtfkmzy(xelsnpykrw) = Urinary tract infection occurred in 2 empagliflozin-treated patients vs. none in placebo, and acute kidney injury in one placebo-treated patient lktntjuykn (czazaeigil ) View more	Positive	24 Oct 2026
				Placebo
ASN2026	Not Applicable	Chronic Kidney Diseases	12	ARB + SGLT2i	gvzakljfte(gngewcyxik) = No specific adverse events were observed among other LT recipients who continued receiving SGLT2i. hxspuimfnz (fgszygcldv )	Positive	23 Oct 2026
				SGLT2i
NCT05305495 (DRIP-AHF, ASN2026)	Phase 2	Chronic Kidney Diseases \| Acute decompensated heart failure	25	Empagliflozin plus furosemide	txyhmwwntb(fjwylstcas) = gxyitfnrin snapdechln (flrmvvjwjj ) View more	Positive	23 Oct 2026
EASD2026	Phase 3	Diabetes Mellitus, Type 2	170	Empagliflozin 10 mgMetforminEvogliptinzin 10 mg + Empagliflozin 10 mgMetforminEvogliptin + Empagliflozin 10 mgMetforminEvogliptin	ubmrmfjmcg(ecxqiqqrtv) = wuskmgvyjf fnhxuuwpvx (frtxrkgscq ) View more	Positive	28 Sep 2026
				Empagliflozin 25 mgMetforminEvogliptinzin 25 mg + Empagliflozin 25 mgMetforminEvogliptin + Empagliflozin 25 mgMetforminEvogliptin	ubmrmfjmcg(ecxqiqqrtv) = xfkadaqhpo fnhxuuwpvx (frtxrkgscq ) View more
LIGHT-MCI (EASD2026)	Phase 3	Diabetes Mellitus, Type 2	396	MetforminLiraglutide + MetforminLiraglutide	ltkdktoaox(tjxjksokcm) = eqbmjhnjws ajrerdlnqz (kipszzarkb )	Positive	28 Sep 2026
				EmpagliflozinMetforminozin + EmpagliflozinMetformin	ltkdktoaox(tjxjksokcm) = jqoyyhvfdo ajrerdlnqz (kipszzarkb )
NCT06435858 (SIDIA, CTgov)	Phase 2	Polycystic Kidney, Autosomal Dominant	16	Empagliflozin (Empagliflozin 10 mg)	tfqmxukzdf(kisrjmldlv) = bojnneiscz uvuhfzprue (vaggzkfwwu, qqcmmlidgy - rgtrevtgsq) View more	-	22 Sep 2026
				placebo (Placebo)	tfqmxukzdf(kisrjmldlv) = lbzaqsoukw uvuhfzprue (vaggzkfwwu, obpzyobrhi - ugappxtxah) View more
NCT06149793 (CTgov)	Phase 2/3	Cystic Fibrosis \| Obesity \| Cystic fibrosis related diabetes	8	Empagliflozin (Empagliflozin)	gdrtcfybqb(qhdnozglwv) = graueuswmx ixhcyfonip (bgkiyowggn, 9.7) View more	-	21 Sep 2026
				Placebo Control (Placebo Control)	gdrtcfybqb(qhdnozglwv) = dgdemysxjk ixhcyfonip (bgkiyowggn, 13.3) View more
NCT05254002 (CONFIDENCE, Pubmed \| Hypertension)	Phase 2/3	-	800	Empagliflozin/Finerenone combination therapy	ieligmaorb(ivmxmvqcej) = Combination therapy significantly reduced SBP versus monotherapies in the ≥130 mm Hg (P<0.0001) but not in the <130 mm Hg group. anhamwbudm (zfsjteilax ) View more	Positive	01 Sep 2026
				Finerenone

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis